Garuda Therapeutics develops off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases.
Garuda’s platform for generating off-the-shelf, self-renewing blood stem cells is designed to provide patients with rapid and broad access to consistent, durable, HLA-matched, transgene-free blood stem cell therapies. Currently, patients seeking a blood stem cell transplant, must find a suitable human donor as a source of blood stem cells. Racial minority patients face greater barriers than white patients in finding suitable blood stem cell matches.
As the industry’s first off-the-shelf offering, Garuda says its technology has the potential to cure more than 70 diseases and eliminate dependency on donor or patient cells.
Garuda Therapeutics was founded in 2021 by David Scadden, Dhvanit Shah, Sean Morrison. In September 2021, the company raised US$72 million in their Series A round.
Subscribe for alerts on new companies featured on Startups.Bio
The biotechnology sector is advancing rapidly, fueled by significant venture capital investments that are enabling companies to achieve major breakthroughs. To stay informed about the latest funding activities and discover …
Founded in 2024, Analona Therapeutics is a biotech company located in Denmark focused on developing innovative antibody-based therapies for pancreatic cancer. The company is built on cutting-edge research from the …
U-Ploid Biotechnologies aims to revolutionize IVF for Age-Related Infertility. Millions of women around the world face the emotional and financial toll of age-related infertility. As more individuals choose to start …
BioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on the development of small molecules to inhibit biofilm formation, which causes 80% of chronic and recurrent infections. BioTryp's …